IMMX News and Press, Immix Biopharma Inc.

2026-06-02 10:20:39 ET More on Biohaven, Greenwich Lifesciences, etc. Sellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL Readout Biohaven: Despite Today's Gains, I Remain Skeptical Savara: The Rare Disease Funnel Is Becoming A Commercial As...

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”)...

2026-05-22 12:15:05 ET Robert Burns from H.C. Wainwright issued a price target of $20.00 for IMMX on 2026-05-22 14:38:53. The adjusted price target was set to $20.00. At the time of the announcement, IMMX was trading at $8.915. The overall price target consensus is at $1...

2026-05-21 09:34:23 ET Denver, Colorado ( www.247marketnews.com ) – Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum ...

2026-05-21 07:53:24 ET More on Immix Biopharma, Inc. Immix rises after mid-stage trial data for AL amyloidosis therapy Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Histori...

2026-05-21 07:02:11 ET More on Immix Biopharma, Inc. Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information ...

LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,77...

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  – –   CR rate now 95% (19 of 20 patients)   – –    All CRs reached within 1 year of follow-up post-...

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and ho...

– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson ...